<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NATEGLINIDE</span><br/>(nat-e'gli-nide)<br/><span class="topboxtradename">Starlix<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">antidiabetic</span>; <span class="classification">meglitinide</span><br/><b>Prototype: </b>Repaglinide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>60 mg, 120 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Lowers blood glucose levels by stimulating the release of insulin from the pancreatic cells of a type 2 diabetic.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Significantly reduces postprandial blood glucose in type 2 diabetics and improves glycemic control when given before meals.
         There is minimal risk of hypoglycemia. Indicated by preprandial blood glucose between 80120 mg/dL and HbA<sub>1c</sub>
</p><h1><a name="uses">Uses</a></h1>
<p>Alone or in combination with metformin for the treatment of non-insulin dependent diabetes mellitus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prior hypersensitivity to nateglinide. Type 1 (insulin-dependent) diabetes mellitus, diabetic ketoacidosis; pregnancy (category
         B), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; liver dysfunction; adrenal or pituitary insufficiency; malnutrition; infection, trauma, surgery or unusual
         stress; concurrent therapy of drugs which inhibit cytochrome P450-3A4 (e.g. erythromycin, ketoconazole); concurrent therapy
         with drugs which are inducers of cytochrome P450-3A4 (e.g. rifampin); other medications, especially beta-adrenergic blocking
         agents.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60120 mg t.i.d. 130 min prior to meals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give, preferably, 10 min before meals. Omit the dose if the meal is skipped. Add a dose if an extra meal is eaten. Never double
            the dose.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, flu-like symptoms. <span class="typehead">CV:</span> Dizziness. <span class="typehead">GI:</span> Diarrhea. <span class="typehead">Metabolic:</span> Hypoglycemia. <span class="typehead">Musculoskeletal:</span> Arthropathy. <span class="typehead">Respiratory:</span> Upper respiratory infection, bronchitis, cough. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">nsaid</span>s, <span class="classification">salicylates</span>, <span class="classification">mao inhibitors</span>, <span class="classification">beta-adrenergic blockers</span>, may potentiate hypoglycemic effects; <span class="classification">thiazide diuretics</span>, <span class="classification">corticosteroids</span>, <span class="classification">thyroid preparations</span>, <span class="classification">sympathomimetic agents</span> may attenuate hypoglycemic effects. <span class="typehead">Herbal:</span> <b>Garlic,</b> <b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 73% bioavailability. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP2C9 (70%) and CYP3A4 (30%). <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 1.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Frequent FBS monitoring and HbA<sub>1C</sub> q3mo to determine effective dose.
         </li>
<li>Monitor carefully for S&amp;S of hypoglycemia especially during the one-week period following transfer from a longer acting sulfonylurea
            such as chlorpropamide.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take only before a meal to lessen the chance of hypoglycemia.</li>
<li>When transferred to nateglinide from another oral hypoglycemia drug, start nateglinide the morning after the other agent is
            stopped, unless directed otherwise by physician.
         </li>
<li>Watch for S&amp;S of hyperglycemia or hypoglycemia (see Appendix F); report poor blood glucose control to physician.</li>
<li>Report gastric upset or other bothersome GI symptoms to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>